Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | HINT1 | P49773 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19887006 | 1.00 | POLB (0.52) | POLBFUT5HPRT1P2RY2P2RY4 | |
| SCHEMBL15280795 | 0.93 | POLB (0.54) | POLBFUT5HPRT1P2RY2P2RY4 | |
| SCHEMBL18057134 | 0.93 | POLB (0.54) | POLBFUT5HPRT1P2RY2P2RY4 | |
| SCHEMBL24784387 | 0.93 | POLB (0.54) | POLBFUT5HPRT1P2RY2P2RY4 | |
| SCHEMBL15280862 | 0.92 | POLB (0.55) | POLBFUT5HPRT1P2RY2P2RY4 | |
| SCHEMBL16587303 | 0.91 | POLB (0.57) | POLBFUT5HPRT1P2RY2P2RY4 | |
| SCHEMBL15280813 | 0.91 | POLB (0.57) | POLBFUT5HPRT1P2RY2P2RY4 | |
| SCHEMBL24699701 | 0.86 | POLB (0.55) | POLBFUT5HPRT1P2RY2P2RY4 | |
| SCHEMBL18057119 | 0.86 | POLB (0.51) | POLBFUT5HPRT1P2RY2P2RY4 | |
| SCHEMBL19887003 | 0.86 | POLB (0.51) | POLBFUT5HPRT1P2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172903-A1 | ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION | OSAKA UNIVERSITY (JP) | 2020-06-04 | — | — | US | disclosed |
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | POLB 394/4885FUT5 1861/4885HPRT1 1267/4885 |
| US-20200172903-A1 | ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION | SNCA, ENO1, ENY2 | POLB 89/4885FUT5 3419/4885HPRT1 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.